ClinicalTrials.gg
Not yet recruitingNCT06999239Updated Jun 13, 2025

Evaluation of the Effect of Laser Therapy on Lateral Pterygoid Muscle in Patients With Wilke's Stage I and II Temporomandibular Disorders (TMD): Case Series Study

An interventional study of laser therapy in TMD in Laser, Temporomandibular Joint Disorders and Lateral Pterygoid Muscle, sponsored by Cairo University. Not yet recruiting. Open to participants aged 16 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
16 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Temporomandibular Joint Disorders by Cairo University — 8 open to participants now, 9 under way, none of them phase 3. Temporomandibular Joint Disorders · Cairo University.

Planned enrollment
15th of 21
25 · median 29
Started
2025
with 3 others
No phase
20 of 30
7 open now
Registered
25th of 30
by date

Among the 30 studies in Temporomandibular Joint Disorders by Cairo University, this one is the 15th largest by planned enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2025, is one of 20 with no phase, and was the 25th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

8 of the 30 studies in Temporomandibular Joint Disorders by Cairo University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 16 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Temporomandibular Joint Disorders by Cairo University, or all of them as a file.
02

Study summary

The purpose of this study will be to evaluate the effect of laser therapy on lateral pterygoid muscle in patients with Wilke's stage I and II temporomandibular disorders (TMD).

03

Conditions studied

  • Laser
  • Temporomandibular Joint Disorders
  • Lateral Pterygoid Muscle

Keywords

  • laser therapy, lateral pterygoid muscle, Wilke's, stage I and II, TMD.
04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients age between 16-50 years with no sex predilection.
  2. Patients who will be free from any systemic diseases that affect temporomandibular joint.
  3. Patients who will be diagnosed with wilk's stage I and II temporomandibular disorders (TMD).
  4. Patients who will be ready to give .

Exclusion criteria

Exclusion Criteria:

  1. Patients with previous temporo-mandibular surgeries.
  2. Patients with previous facial fracture.
  3. Patients who will be under another type of treatment for TMD (e.g., occlusal splints, pharmacological drugs, or head and neck surgery).
  4. Patients who will not attend the proposed treatment sessions or follow-up visits.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    one arm(case series0

    Procedure: laser therapy in TMD

Interventions

  • Procedurelaser therapy in TMD

    In this study patients will receive the Low-level laser therapy with a 635 nm wavelength diode laser (Lasotronix, Diode Laser DiodeLX model SMART M; Zytnia, Piaseczno, Poland) with 200 mW in a continuous mode, using a handpiece with a cylindrical applicator with a diameter of 8 mm in contact mode extra-orally, fiber-optic applicator with a diameter of 8 mm in contact mode intraorally, with a power density of 400 mW/cm2, delivering 10-12 J/cm2 on each application point, over a period of 20 sec. There are two methods for examination of lateral pterygoid muscle: digital palpation and functional manipulation. For digital palpation of lateral pterygoid muscle, we place our index finger or tip of our little finger in the vestibular area adjacent to the maxillary third molar. Functional manipulation of the inferior head of lateral pterygoid muscle: It is best accomplished by having the patient make a protrusive movement against resistance to contract it since this muscle is the primary pro

06

What researchers measure

Primary outcomes

  1. Pain: will be obtained by Visual analogue scale (VAS).

    Pain: will be obtained by Visual analogue scale (VAS).

    Time frame: pain will be measured : 1.day1 before the start of laser therapy, 2.week 1 3. week2 4.week 3 5. week 4 6.one month later 7. 3 months later.

Secondary outcomes

  1. Mouth opening, lateral protrusive movement: will be obtained by a caliper.

    Mouth opening, lateral protrusive movement: will be obtained by a caliper.

    Time frame: Mouth opening, lateral protrusive movement will be measured : 1.day1 before the start of laser therapy, 2.week 1 3. week2 4.week 3 5. week 4 6.one month later 7. 3 months later.

Other outcomes

  1. Clicking: will be obtained by Yes or No.

    Clicking: will be obtained by Yes or No.

    Time frame: Clicking will be measured : 1.day1 before the start of laser therapy, 2.week 1 3. week2 4.week 3 5. week 4 6.one month later 7.after 3 months.

  2. Clicking: will be obtained by Yes or No.

    Clicking: will be obtained by Yes or No.

    Time frame: Clicking will be measured : 1.day1 before the start of laser therapy, 2.week 1 3. week2 4.week 3 5. week 4 6.one month later 7. 3 months later.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jul 2026, 12 months later.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 12 months is close to that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 31, 2025
StartEst.
Jul 2025
Primary completionEst.
Jul 2026
CompletionEst.
Aug 2026
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06999239
Lead sponsor
Cairo University
Responsible party
Aliaa ibrahim fathy (doctor, Cairo University) — Principal investigator
First posted
May 31, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jun 13, 2025

Study contacts

aliaa ibrahim fathy khalifa, B.D.S 2019
Contact
aliaa.ibrahim@dentistry.cu.edu.com
01068111549

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion